Market access & commercial

Digital marketplaces and distributor platforms that let a product formulator search, compare and directly source specialty and bio-based ingredients — flavors, actives, functional ingredients — across many suppliers from one catalog, replacing the phone-and-sample-based sourcing process a formulation team used to run supplier by supplier.

Specialist logistics and customs-brokerage firms that clear biological materials, pharmaceuticals, clinical-trial specimens and cell/gene therapies through import and export customs, managing temperature-controlled shipping, importer-of-record liability and country-specific biological import permits.

Software platforms and data providers that classify controlled biotechnology and life-science goods, screen counterparties against denied-party and sanctions lists, and trace supply-chain and ownership networks so exporters of dual-use bio-related technology stay inside US, EU and allied export-control regimes.

Market-research firms and platforms that run qualitative focus groups and quantitative A/B/concept testing with ordinary consumers — not trained sensory panelists — to validate bio-based product concepts, claims, packaging and messaging before a launch commits to production.

Platforms and 3PL operators that manage the distribution, tracking and Prescription Drug Marketing Act (PDMA) compliance of physician product samples for pharmaceutical and biotech companies — the specific logistics and compliance layer that gets a physical drug sample from manufacturer to prescriber legally and traceably.

Market-intelligence and LCA consulting that screens which petrochemical building blocks can be feasibly swapped for bio-based drop-in equivalents, verifies renewable-carbon-share claims for regulators and brand customers, and models the cost-parity timeline against fossil incumbents.

Matching platforms and contract manufacturers that connect biotech companies needing fermentation capacity with idle or available bioreactor capacity, easing the scale-up bottleneck between lab-scale precision fermentation and commercial-volume production.

Specialist research organizations that build the economic and clinical-outcomes evidence pharmaceutical and biotech companies need to justify a product's value to payers and health-technology-assessment bodies — modeling cost-effectiveness, synthesizing real-world evidence and preparing HTA dossiers.

Health-economic evidence packages — systematic clinical-evidence reviews, cost-effectiveness and budget-impact modeling, patient-perspective data — that a biopharma manufacturer must assemble to win pricing and reimbursement approval from a national HTA body (NICE, G-BA, CADTH), prepared by specialty consultancies against strict statutory deadlines (56 days for a NICE Single Technology Appraisal), increasingly using AI to compress a traditionally months-long process.

Contract development, technology-transfer and local-build services that establish in-country or regional biomanufacturing so a biologic or vaccine qualifies for market access, procurement preference and supply security in target jurisdictions.

Software platforms and CRM systems purpose-built for pharma medical-affairs teams — continuing medical education content, medical science liaison (MSL) field engagement, and medical-inquiry management — that keep scientific-exchange activity separate from and compliant alongside commercial sales.

Consultancies that secure CPT/HCPCS billing codes, payer coverage policies and national health-insurance listings for medical devices — turning FDA clearance into an actual reimbursement pathway that determines whether hospitals and clinicians will be paid to use the device.

Regulatory-affairs firms that register bio-based consumer products — novel foods, cosmetics, food-contact materials and new ingredients — across multiple national regimes simultaneously (US FDA/MoCRA, EU Novel Food, China's new-ingredient system), distinct from biopharmaceutical drug-submission consulting.

Regulated pre-approval access to investigational biopharmaceuticals for patients with serious or life-threatening disease and no satisfactory alternative — operated as a managed-access service spanning eligibility, regulatory submission, GMP drug sourcing and pharmacovigilance.

Specialist firms and software platforms that manage a biotech or pharmaceutical patent portfolio from filing through expiration — tracking deadlines, paying renewal annuities across every jurisdiction where a patent is active, and flagging expiration dates that determine when generic or biosimilar competition can enter.

Specialist firms that recruit, train and run trained descriptive sensory panels and consumer taste tests for food, beverage and CPG manufacturers, translating tasted attributes into the data that guides reformulation and label claims.